Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 9/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4016044 | 0.91 | CYP1A2 (0.41) | APPCYP19A1CYP2C9CYP2C19 | |
| SCHEMBL4014916 | 0.89 | APP (0.43) | APPMAPTKDM4EMEN1KMT2A | |
| SCHEMBL4017940 | 0.72 | MAPT (0.44) | APPMAPT | |
| SCHEMBL8368668 | 0.71 | LSS (0.56) | MAPTKDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL10458215 | 0.71 | APP (0.53) | APPMAPTCYP3A4CYP2D6 | |
| SCHEMBL16581451 | 0.69 | ALDH1A1 (0.59) | MEN1KMT2AFFAR1FFAR4GP6 | |
| SCHEMBL4016046 | 0.69 | DRD3 (0.44) | APPMAPTCYP19A1CYP2C9CYP2C19 | |
| SCHEMBL24921144 | 0.68 | TDO2 (0.51) | MAPTKDM4EKMT2ACYP3A4CYP2D6 | |
| SCHEMBL4014920 | 0.68 | PARP1 (0.42) | APPMAPTKDM4EMEN1KMT2A | |
| SCHEMBL4830146 | 0.66 | HSD17B1 (0.58) | CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7632851-B2 | Benzo[1,2,5]oxadiazoles and benzol[1,2,5]thiadiazoles useful as histopathological staining agents, imaging agents and biomarkers | NOVARTIS AG (CH) | 2009-12-15 | — | — | US | disclosed |
| EP-1613610-B1 | BENZO 1,2,5 OXADIAZOLES AND BENZO 1,2,5 THIADIAZOLES USEFUL AS HISTOPATHOLOGICAL STAINING AGENTS, IMAGING AGENTS AND BIOMARKERS | NOVARTIS AG (CH) | 2009-07-01 | — | — | EP | disclosed |
| US-20060093551-A1 | Benzo[1,2,5]oxadiazoles and benzol[1,2,5]thiadiazoles useful as histopathological staining agents, imaging agents and biomarkers | NOVARTIS AG (CH) | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060093551-A1 | Benzo[1,2,5]oxadiazoles and benzol[1,2,5]thiadiazoles useful as histopathological staining agents, imaging agents and biomarkers | H1-3, MKI67, H1-5 | APP 3464/4885MAPT 2136/4885KDM4E 3716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.